SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Calamari Christopher J.

(Last) (First) (Middle)
100 ABBOTT PARK ROAD

(Street)
ABBOTT PARK IL 60064

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2021
3. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SENIOR VICE PRESIDENT
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares without par value 12,156 D
Common shares without par value 30,193 I The Calamari Family Trust
Common shares without par value 100(1) I Profit Sharing Trust
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy)(2) 02/16/2019 02/15/2028 Common Shares 51,559 59.94 D
Option (right to buy)(3) 02/22/2020 02/21/2029 Common Shares 42,009 75.9 D
Option (right to buy)(4) 02/21/2021 02/20/2030 Common Shares 37,081 87.72 D
Option (right to buy)(5) 02/19/2022 02/18/2031 Common Shares 27,840 124.04 D
Explanation of Responses:
1. Balance in the Abbott Laboratories Stock Retirement Trust as of July 1, 2021.
2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 17,187 on February 16, 2019, 17,187 on February 16, 2020 and 17,186 on February 16, 2021.
3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 14,003 on February 22, 2020 and 14,003 on February 22, 2021, and an increment of 14,003 becomes exercisable on February 22, 2022.
4. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in an annual increment of 12,360 on February 21, 2021 and annual increments of 12,360 and 12,361 become exercisable on February 21, 2022 and February 21, 2023, respectively.
5. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,280 on February 19, 2022, 9,280 on February 19, 2023, and 9,280 on February 19, 2024.
/s/ Christopher J. Calamari by Jessica H. Paik, Attorney-in-Fact 07/06/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
32L Timeline



EX 24.1



POWER OF ATTORNEY



The undersigned constitutes and appoints HUBERT L. ALLEN, JESSICA H. PAIK, and AARON N. RICE, and each of them individually, as the undersigned’s true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the undersigned and in the undersigned’s name, place and stead, to prepare and sign any and all Securities and Exchange Commission (“SEC”) Notices of Proposed Sales of Securities pursuant to Rule 144 under the Securities Act of 1933 on Form 144, all SEC statements on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, including a Form ID and any other documents necessary to obtain codes and passwords necessary to make electronic filings, and any amendments to such forms, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite, necessary or desirable to be done under said Rule 144 and Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.


A copy of this power of attorney shall be filed with the SEC.  The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to file Forms 144, 3, 4, or 5 or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.




Date:  June 10, 2021


/s/ Christopher J. Calamari

Signature of Reporting Person



Christopher J. Calamari

Abbott Laboratories

100 Abbott Park Road

Abbott Park, IL 60064